MetaCap

Attovia Therapeutics (ATTO) vs Cullinan Therapeutics (CGEM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Attovia Therapeutics is the larger company by market cap ($690.3 million vs $577.1 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATTO-31.05%CGEM-49.52%
+34%-10%-54%
Aug 5, 20261 yearNov 20, 2026
ATTO-25.14%CGEM-49.86%
+30%-12%-54%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATTO versus CGEM key metrics
MetricATTOCGEM
Share price$15.10$8.89
Market cap$690.26M$577.15M
1-day change-3.08%-1.98%
YTD return—-14.11%
1-year return—-6.12%
5-year return—-51.21%
EPS (TTM)$-5.53$-3.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-219.88M
52-week high$28.00$23.19
52-week low$12.94$8.47
Distance from 52-week high-46.07%-61.66%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+186.09%+285.49%
Average volume337.27K997.14K
Shares outstanding45.71M64.92M
Employees50109
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Attovia Therapeutics

ATTO stock →

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees

About Cullinan Therapeutics

CGEM stock →

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

ATTO vs CGEM FAQ

Which is bigger, Attovia Therapeutics or Cullinan Therapeutics?

Attovia Therapeutics (ATTO) is larger, with a market capitalization of $690.26M compared with $577.15M for Cullinan Therapeutics (CGEM).

Are Attovia Therapeutics and Cullinan Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons